These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35513899)

  • 21. Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.
    Inatani M; Orii Y; Iwasaki K; Arimura S; Sunagawa H; Shiokawa M; Inoue K; Sakono T; Sakono T; Kuwamura R; Yoshida A; Oi J; Kuwayama Y; Kano K; Kido N; Matsuyama A; Ozaki M; Abe H; Inoue C; Nakagawa S; Musashi K; Kanamori A; Lee J; Otani S; Aoki R; Tanabe H; Nakakura S; Suzuki K; Sagara T; Saito Y; Sameshima M; Urahashi M; Watanabe-Kitamura F; Inoue T; Kagaya F; Murai Y; Mori S; Ueda K; Kurimoto T; Yamada-Nakanishi Y; Nakamura M; Yamashita T; Ishiyama S; Manabe S; Takaki K; Hayashi K; Ishida A; Tsutsui A; Manabe K; Tanito M
    Adv Ther; 2023 Sep; 40(9):4074-4092. PubMed ID: 37452961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily.
    Stewart WC; Stewart JA; Day D; Sharpe ED
    Acta Ophthalmol Scand; 2003 Jun; 81(3):242-6. PubMed ID: 12780402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension.
    Ling Z; Zhang M; Hu Y; Yin Z; Xing Y; Fang A; Ye J; Chen X; Liu D; Wang Y; Sun W; Dong Y; Sun X
    Chin Med J (Engl); 2014; 127(5):905-10. PubMed ID: 24571886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
    Schuman JS
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension.
    Whitcup SM; Cantor LB; VanDenburgh AM; Chen K
    Br J Ophthalmol; 2003 Jan; 87(1):57-62. PubMed ID: 12488264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
    Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma.
    Konstas AG; Stewart WC; Topouzis F; Tersis I; Holmes KT; Stangos NT
    Am J Ophthalmol; 2001 Jun; 131(6):729-33. PubMed ID: 11384568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: a six-month, double-masked, multicenter study.
    Shedden A; Laurence J; Tipping R;
    Clin Ther; 2001 Mar; 23(3):440-50. PubMed ID: 11318078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.
    Williams RD; Cohen JS; Gross RL; Liu CC; Safyan E; Batoosingh AL;
    Br J Ophthalmol; 2008 Oct; 92(10):1387-92. PubMed ID: 18621791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination.
    Day DG; Sharpe ED; Beischel CJ; Jenkins JN; Stewart JA; Stewart WC
    Eur J Ophthalmol; 2005; 15(3):336-42. PubMed ID: 15945001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension.
    Goldberg I; Cunha-Vaz J; Jakobsen JE; Nordmann JP; Trost E; Sullivan EK;
    J Glaucoma; 2001 Oct; 10(5):414-22. PubMed ID: 11711841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
    Schuman JS
    Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension.
    Hughes BA; Bacharach J; Craven ER; Kaback MB; Mallick S; Landry TA; Bergamini MV
    J Glaucoma; 2005 Oct; 14(5):392-9. PubMed ID: 16148589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of fixed-combination brimonidine tartrate/timolol maleate in primary open-angle glaucoma, including normal-tension glaucoma.
    Park SW; Kim JM; Lee JW; Maglambayan J; Simonyi S; Park KH
    Jpn J Ophthalmol; 2021 Mar; 65(2):295-305. PubMed ID: 33591471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Brimonidine and Timolol on the Progression of Visual Field Defects in Open-angle Glaucoma: A Single-center Randomized Trial.
    Yokoyama Y; Kawasaki R; Takahashi H; Maekawa S; Tsuda S; Omodaka K; Nakazawa T
    J Glaucoma; 2019 Jul; 28(7):575-583. PubMed ID: 31188229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
    Frampton JE
    Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.
    Hommer A; Kapik B; Shams N;
    Br J Ophthalmol; 2003 May; 87(5):592-8. PubMed ID: 12714402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).
    Medeiros FA; Walters TR; Kolko M; Coote M; Bejanian M; Goodkin ML; Guo Q; Zhang J; Robinson MR; Weinreb RN;
    Ophthalmology; 2020 Dec; 127(12):1627-1641. PubMed ID: 32544560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
    Coleman AL; Lerner F; Bernstein P; Whitcup SM
    Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.